


## FLDP-5

<b>Cat. No.:</b>	HY-150791
<b>CAS No.:</b>	950665-12-0
<b>Molecular Formula:</b>	C <sub>21</sub> H <sub>21</sub> NO <sub>5</sub>
<b>Molecular Weight:</b>	367.4
<b>Target:</b>	Reactive Oxygen Species; DNA/RNA Synthesis
<b>Pathway:</b>	Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Cell Cycle/DNA Damage
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

Description	FLDP-5 is a blood-brain barrier (BBB) penetrant curcuminoid analogues. FLDP-5 can induce production of ROS (Reactive Oxygen Species), DNA damage and cell cycle S phase arrest. FLDP-5 exhibits highly potent tumour-suppressive effects with anti-proliferative and anti-migratory activities on LN-18 cells <sup>[1]</sup> .																
<b>In Vitro</b>	<p>FLDP-5 (0-20 μM; 24 h) has cytotoxicity on human glioblastoma multiforme (GBM) LN-18 cells and HBEC-5i<sup>[1]</sup>.</p> <p>FLDP-5 (2.5 μM; 0-6 h) induces superoxide and hydrogen peroxide in LN-18 cell death<sup>[1]</sup>.</p> <p>FLDP-5 (2.5 μM; 0-4 h) induces DNA damage with a time-dependent manner in LN-18 cells<sup>[1]</sup>.</p> <p>FLDP-5 (1.25 and 2.5 μM; 24 and 48 h) potentiates anti-migration effects in LN-18 cells<sup>[1]</sup>.</p> <p>FLDP-5 (1.25 and 2.5 μM; 24 h) reduces the percentage of relative invasion in LN-18 cells in a significant dose-dependent manner<sup>[1]</sup>.</p> <p>FLDP-5 (0.625 and 1.25 μM; 24 h) induces arrest in S phase in a concentration-dependent manner<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Cytotoxicity Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>LN-18 and HBEC-5i cells</td> </tr> <tr> <td>Concentration:</td> <td>0-20 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 h</td> </tr> <tr> <td>Result:</td> <td>Exhibited cytotoxicity on human GBM LN-18 cells and HBEC-5i with IC<sub>50</sub>s of 2.4 μM and 5.6 μM.</td> </tr> </table> <p>Cell Migration Assay<sup>[1]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>LN-18 cells</td> </tr> <tr> <td>Concentration:</td> <td>1.25 and 2.5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 and 48 h</td> </tr> <tr> <td>Result:</td> <td>Potentiated anti-migration effects in LN-18 cells with wound closure of 56.43% ± 6.28 and 3.17% ± 0.71 at 1.25 μM and 2.5 μM (48 h), respectively.</td> </tr> </table> <p>Cell Invasion Assay<sup>[1]</sup></p>	Cell Line:	LN-18 and HBEC-5i cells	Concentration:	0-20 μM	Incubation Time:	24 h	Result:	Exhibited cytotoxicity on human GBM LN-18 cells and HBEC-5i with IC <sub>50</sub> s of 2.4 μM and 5.6 μM.	Cell Line:	LN-18 cells	Concentration:	1.25 and 2.5 μM	Incubation Time:	24 and 48 h	Result:	Potentiated anti-migration effects in LN-18 cells with wound closure of 56.43% ± 6.28 and 3.17% ± 0.71 at 1.25 μM and 2.5 μM (48 h), respectively.
Cell Line:	LN-18 and HBEC-5i cells																
Concentration:	0-20 μM																
Incubation Time:	24 h																
Result:	Exhibited cytotoxicity on human GBM LN-18 cells and HBEC-5i with IC <sub>50</sub> s of 2.4 μM and 5.6 μM.																
Cell Line:	LN-18 cells																
Concentration:	1.25 and 2.5 μM																
Incubation Time:	24 and 48 h																
Result:	Potentiated anti-migration effects in LN-18 cells with wound closure of 56.43% ± 6.28 and 3.17% ± 0.71 at 1.25 μM and 2.5 μM (48 h), respectively.																

Cell Line:	LN-18 cells
Concentration:	1.25 and 2.5 $\mu$ M
Incubation Time:	24 h
Result:	Reduced the percentage of relative invasion in LN-18 cells in a significant dose-dependent manner.

#### Cell Cycle Analysis<sup>[1]</sup>

Cell Line:	LN-18 cells
Concentration:	0.625 and 1.25 $\mu$ M
Incubation Time:	24 h
Result:	Induced arrest in S phase in a concentration-dependent manner, and exhibited accumulation of 63.38% $\pm$ 4.42 at 1.25 $\mu$ M.

## REFERENCES

[1]. Razali NSC, et al. Curcumin piperidone derivatives induce anti-proliferative and anti-migratory effects in LN-18 human glioblastoma cells. Sci Rep. 2022 Jul 30;12(1):13131.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA